Invent Medic’s innovative medical technology product Efemia Bladder Support was shown to significantly improve quality of life for 75% of the participants in a follow-up study with women that participated in the company’s clinical study.

The follow-up study was conducted to improve the knowledge on how Efemia effects self-reported quality of life in women with clinically diagnosed stress urinary incontinence. 40 women were invited to participate in the study. Of these, 28 accepted and completed the whole study. Professor Aino Fianu Jonasson, specialist in urogynecology at the Karolinska University Hospital, was the principal investigator of the study.

“It is satisfying that Efemia works so well over time for women with diagnosed stress urinary incontinence. The results show that we have been able to create a well-performing solution for this important target group, including a convenient size so that the product is easy to carry around and use when needed,” says Invent Medic’s CEO Karin Bryder.

In addition to 75% of the participants stating that Efemia improved their quality of life, 68% answered that they will continue to use the product after the study. Moreover, 82% stated that they would recommend it to a friend or colleague.

“This study clearly shows that Efemia users tend to become ambassadors for the product, which is a positive sign for the future. We know that many women take some time before they start using this type of product, and a personal recommendation can be crucial to take that final step,” says Karin Bryder.

Efemia is available to purchase for personal use and by companies through Arcamea, Invent Medic’s brand for women’s health products. Arcamea’s webshop can be found at http://www.arcamea.se. The product is also available to purchase online via Sweden’s two largest pharmacy chains, Apoteket AB and Apotek Hjärtat. The company is in discussions with additional pharmacy chains and health care providers with the aim to broaden the product’s availability and visibility.

Download: Read as PDF.